Skip header and navigation
CMA PolicyBase

Policies that advocate for the medical profession and Canadians


3 records – page 1 of 1.

Psycho-active substances and the operation of motor vehicles and industrial equipment

https://policybase.cma.ca/en/permalink/policy781
Last Reviewed
2017-03-04
Date
1973-06-16
Topics
Pharmaceuticals/ prescribing/ cannabis/ marijuana/ drugs
Population health/ health equity/ public health
Resolution
GC73-50
That the membership of the Canadian Medical Association clearly inform its patients, and the general public at large, of the hazards associated with the operation of motor vehicles, industrial equipment, etc., while under the influence of psycho-active substances, especially alcohol and antihistamines, and particularly the combination of such substances.
Policy Type
Policy resolution
Last Reviewed
2017-03-04
Date
1973-06-16
Topics
Pharmaceuticals/ prescribing/ cannabis/ marijuana/ drugs
Population health/ health equity/ public health
Resolution
GC73-50
That the membership of the Canadian Medical Association clearly inform its patients, and the general public at large, of the hazards associated with the operation of motor vehicles, industrial equipment, etc., while under the influence of psycho-active substances, especially alcohol and antihistamines, and particularly the combination of such substances.
Text
That the membership of the Canadian Medical Association clearly inform its patients, and the general public at large, of the hazards associated with the operation of motor vehicles, industrial equipment, etc., while under the influence of psycho-active substances, especially alcohol and antihistamines, and particularly the combination of such substances.
Less detail

Adverse reactions between alcohol and drug products

https://policybase.cma.ca/en/permalink/policy805
Last Reviewed
2017-03-04
Date
1987-08-25
Topics
Pharmaceuticals/ prescribing/ cannabis/ marijuana/ drugs
Resolution
GC87-31
That the Canadian Medical Association urge appropriate agencies to adopt regulations and/or policies to ensure that warnings about the adverse interaction between alcohol and both prescription and non-prescription products be prominently displayed or distributed wherever alcohol and drugs are sold and/or dispensed.
Policy Type
Policy resolution
Last Reviewed
2017-03-04
Date
1987-08-25
Topics
Pharmaceuticals/ prescribing/ cannabis/ marijuana/ drugs
Resolution
GC87-31
That the Canadian Medical Association urge appropriate agencies to adopt regulations and/or policies to ensure that warnings about the adverse interaction between alcohol and both prescription and non-prescription products be prominently displayed or distributed wherever alcohol and drugs are sold and/or dispensed.
Text
That the Canadian Medical Association urge appropriate agencies to adopt regulations and/or policies to ensure that warnings about the adverse interaction between alcohol and both prescription and non-prescription products be prominently displayed or distributed wherever alcohol and drugs are sold and/or dispensed.
Less detail

Drug product substitution

https://policybase.cma.ca/en/permalink/policy806
Last Reviewed
2017-03-04
Date
1987-08-25
Topics
Pharmaceuticals/ prescribing/ cannabis/ marijuana/ drugs
Resolution
GC87-39
The Canadian Medical Association supports the position that: 1) a patient should have the right to choose either a generic or a brand-name prescription drug where both alternatives exist; and 2) a physician should have the right to order "no substitution" of a drug product he or she prescribes.
Policy Type
Policy resolution
Last Reviewed
2017-03-04
Date
1987-08-25
Topics
Pharmaceuticals/ prescribing/ cannabis/ marijuana/ drugs
Resolution
GC87-39
The Canadian Medical Association supports the position that: 1) a patient should have the right to choose either a generic or a brand-name prescription drug where both alternatives exist; and 2) a physician should have the right to order "no substitution" of a drug product he or she prescribes.
Text
The Canadian Medical Association supports the position that: 1) a patient should have the right to choose either a generic or a brand-name prescription drug where both alternatives exist; and 2) a physician should have the right to order "no substitution" of a drug product he or she prescribes.
Less detail